

Datasheet for ABIN2667435 IL29 Protein (AA 23-200)



Overview

Quantity:	20 µg
Target:	IL29
Protein Characteristics:	AA 23-200
Origin:	Chemical
Source:	Escherichia coli (E. coli)
Protein Type:	Recombinant
Biological Activity:	Active
Application:	Flow Cytometry (FACS)
Product Details	
Purity:	>98 % , as determined by Coomassie stained SDS-PAGE.
Endotoxin Level:	Less than 0.1 ng per µg of protein.
Target Details	
Target:	IL29
Alternative Name:	IFN-1 (IL29 Products)
Background:	IFN- $\lambda$ 1, also known as IL-29, is a member of the type III interferon (IFN) family. Type III
	interferons, including IFN- $\lambda$ 1, IFN- $\lambda$ 2 and IFN- $\lambda$ 3, are produced upon virus infection and are
	functionally similar to type I interferon (IFN- $\alpha/\beta$ ). IFN- $\lambda$ binds to a heterodimeric receptor
	composed of the IFN- $\lambda$ receptor 1 (IFNLR1) and the interleukin-10 receptor 2 (IL-10R2),
	subsequently tranducing signal through the JAK-STAT pathway and leading to transactivation

Order at www.antibodies-online.com | www.antikoerper-online.de | www.anticorps-enligne.fr | www.antibodies-online.cn International: +49 (0)241 95 163 153 | USA & Canada: +1 877 302 8632 | support@antibodies-online.com Page 1/2 | Product datasheet for ABIN2667435 | 07/26/2024 | Copyright antibodies-online. All rights reserved.

	of various IFN-stimulated genes (ISGs). IFN- $\lambda$ has been demonstrated to mediate an antiviral
	immune response against several viruses, such as hepatitis B virus (HBV), hepatitis C virus
	(HCV), and human immunodeficiency virus (HIV). In contrast to type I or type II interferons, IFN-
	$\lambda$ receptor is expressed preferentially on epithelial-like cells and some immune cells. Because
	the response to IFN- $\lambda$ is highly restricted to certain cell types, IFN- $\lambda$ is considered a potential
	therapuetic agent for the treatment of viral diseases with less side effects when compared with
	type I interferon.
Molecular Weight:	The 178 amino acid recombinant protein has a predicted molecular mass of approximately
	19.8 kDa. The predicted N-terminal amino acid is Pro.

## Application Details

Application Notes:	Optimal working dilution should be determined by the investigator.
Comment:	Biological activity: ED50 = 0.2 - 0.5 ng/ml, corresponding to a specific activity of 2.0 x 106 - 5.0 x 106 units/mg, as measured by its ability to activate STAT phosphorylation in an ISRE Luciferase Reporter Assay using human colon carcinoma COLO205 cells.
Restrictions:	For Research Use only
Handling	

Format:	Lyophilized
Reconstitution:	For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.
Buffer:	Lyophilized, carrier-free.
Handling Advice:	Avoid repeated freeze/thaw cycles.
Storage:	-20 °C
Storage Comment:	Unopened vial can be stored at -20°C or -70°C.